DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.
[1][2] As of June 2014, it is in phase I/phase II clinical trials.
[1][2]
This analgesic-related article is a stub.
You can help Wikipedia by expanding it.